Effects of cisapride on the secretion of pancreatic polypeptide in healthy volunteers.
Plasma human pancreatic polypeptide (hPP) responses to intravenous injections of a new gastric and intestinal motility promoting agent, R51 619 (cisapride), were studied in healthy volunteers. The mean fasting concentrations of plasma hPP (39 +/- 5.4 pg/ml; mean +/- S.E.) were elevated significantly to the peak values of 118 +/- 25.1 pg/ml 30 min after the drug had been given in a dose of 4 mg over 5 min. However, plasma insulin (IRI), glucose and prolactin levels were not elevated. Atropine diminished the cisapride-induced hPP elevation, thereby suggesting that cisapride induced release of acetylcholine but had no antidopaminergic action.
D000328:Adult; D001285:Atropine / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism; D020117:Cisapride; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D010880:Piperidines / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D010880:Piperidines; D010191:Pancreatic Polypeptide; D001285:Atropine; D011388:Prolactin; D020117:Cisapride